Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with a directed share issue
Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

January 31, 2018

The board of directors of Xspray Pharma proposes a directed share issue to be resolved at an extraordinary general meeting, whereby the company will receive approximately SEK 88 million before transaction costs.


The issue proceeds will primarily be invested in the development of new drug candidates, based on Xspray Pharma’s HyNap-platform. The share issue will be fully subscribed in accordance with separate agreements with the selected investors. Shareholders representing approximately 67.2 percent of Xspray Pharma’s shares have undertaken to vote in favor of the share issue at an extraordinary general meeting.

Xspray Pharma AB (publ) is a product development company with several product candidates under clinical development. The company’s shares are admitted to trading on Nasdaq First North.

Vinge’s team consists of Dain Hård Nevonen, Sabina Börjesson, Nils Fredrik Dehlin and Ramin Baradaran.

COP26 - a step in the right direction to achieve the Paris Agreement goals

 On 13 November 2021, the two-week international climate summit COP26, held in Glasgow, UK, was concluded after leaders from over 190 countries agreed on a new deal, the so-called Climate Pact in Glasgow. The aim of COP26 was for leaders from around the world to agree on how to step up global action to tackle the climate crisis. The agreement, which will set the global average temperature increase at between 1.8 and 2.4 degrees Celsius, is a step towards achieving the Paris Agreement's (COP21) more ambitious target of a maximum increase of 1.5 degrees.
June 23, 2022

The EU Court of Justice dismisses Belgium’s request in Opinion 1/20, but points out that the dispute settlement mechanism of ECT is not applicable to ‘intra-EU disputes’

 The Energy Charter Treaty (ECT) is under renegotiation. Its Article 26, which provides a dispute settlement mechanism, has however not been announced as being subject to such renegotiations. On 2 December 2020, Belgium submitted a request to the EU Court of Justice (CJEU) for an opinion on whether the dispute settlement mechanism of the draft ECT, assuming it remains unchanged, could be interpreted as allowing its application intra-European Union, i.e. between an EU Member State and an investor who is a national of another Member State, and whether this would be compatible with the EU Treaties, in particular Article 19 TEU on the role of the CJEU and Article 344 TFEU on the autonomy of EU law.
June 17, 2022

Double win for Vinge at MIP Awards

 As the only Swedish law firm, Vinge has won two awards at the Managing IP Awards 2022. Vinge was awarded Trademark Contentious Firm of the Year and Copyright and Design Firm of the Year.
June 16, 2022